New study: Ozempic and Wegovy protect the Heart

Date:

Share this article:

Del denne artikel:

Millions take Ozempic or Wegovy to shed pounds, but new evidence suggests their benefits again go far deeper.

A major international study led by researchers at University College London has found that semaglutide, the active ingredient in Ozempic and Wegovy, may protect the heart even when users lose little or no weight.

The research, published in The Lancet and funded by Novo Nordisk, followed more than 17,000 adults aged 45 and older who were overweight and had cardiovascular disease.

Over two years, those who received weekly semaglutide injections saw a 20% reduction in heart attacks, strokes, and similar cardiovascular events compared with those who took a placebo.

More than just weight loss

Interestingly, this heart protection appeared across all body types, not just among people with obesity.

Also read: How to keep children safe from the risks of Halloween candy

Even participants with only modest weight loss still showed substantial cardiovascular benefits.

A smaller waistline explained about one-third of the protective effect, according to the study.

But most of the benefit, researchers found, could not be explained by weight change alone.

Rethinking how doctors use GLP-1 drugs

The findings could change how doctors prescribe semaglutide. Professor John Deanfield, who led the study, noted that patients don’t need dramatic weight loss or a high BMI to benefit.

Also read: Reptiles’ pee could hold the key to treating kidney stones and gout

If the goal is to reduce heart disease risk, limiting use to people with the highest BMI doesn’t make sense, he explained.

However, he cautioned that doctors must continue to weigh the drug’s potential side effects against its broader use.

Although this research focused on semaglutide, scientists believe other GLP-1-based medications, a class of drugs originally developed for diabetes, could offer similar cardiovascular protection.

Researchers emphasized the need for future trials to include more diverse participants by sex and ethnicity to better understand how different populations respond to GLP-1 therapy.

Also read: Scientists discovered a method to transform Teflon into toothpaste fluoride

Sources: Science Daily, and The Lancet.

Also read: Study examines the health effects of eating peanut butter daily

Other articles

Researchers ran a two-year walnut trial: The most harmful LDL particles fell

A daily half cup of the nuts trimmed a particularly harmful LDL subtype.

What happens to your heart if you eat one avocado a day?

Researchers say eating one avocado a day may improve a key heart health marker, even without changing the rest of your diet.

Your fish oil supplement may reach your brain but fail to protect your memory

Cerebrospinal fluid samples proved the supplement was getting where it was meant to go. Cognitive tests showed no advantage over placebo.

Want to strengthen your bones? Then take the stairs

More people are climbing stairs at a brisk pace in the hope of strengthening their bones. However, experts say the approach has both benefits and limitations.

Researchers ran a two-year walnut trial: The most harmful LDL particles fell

A daily half cup of the nuts trimmed a particularly harmful LDL subtype.

What happens to your heart if you eat one avocado a day?

Researchers say eating one avocado a day may improve a key heart health marker, even without changing the rest of your diet.

Your fish oil supplement may reach your brain but fail to protect your memory

Cerebrospinal fluid samples proved the supplement was getting where it was meant to go. Cognitive tests showed no advantage over placebo.